Long-term antibody response to inactivated SARS-CoV-2 vaccination in patients with chronic liver disease: A multicenter study - 11/08/23
Summary |
Patients with chronic liver disease (CLD) are at a greater risk of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection. This study investigated the antibody response to inactivated SARS-CoV-2 vaccination in a long-term prospective cohort of CLD patients. The seropositivity rates and antibody concentrations of anti-SARS-CoV-2 NAbs were similar among patients with different severity of CLD 6 months after the third vaccination. In addition, older CLD patients appeared to have lower antibody responses. These data might be helpful to inform vaccine decisions for patients with chronic liver disease.
El texto completo de este artículo está disponible en PDF.Keywords : Chronic liver disease, SARS-CoV-2, Vaccine, Antibody response
Abbreviation : CLD, SARS-CoV-2, Non-ACLD, CACLD, DACLD, NAb, S/CO, IQR
Esquema
Vol 47 - N° 7
Artículo 102150- août 2023 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.